Study guide

6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy

Key Takeaways Explain This Topic AI

Topical corticosteroid potency is matched to the site: low potency on the face, flexures, and genitals, and mid-to-high potency on thick plaques of the trunk and limbs.

Isotretinoin is teratogenic and in Canada is dispensed under a pregnancy prevention programme requiring two negative pregnancy tests and two forms of contraception.

Acute angle-closure glaucoma presents with a red painful eye, a fixed mid-dilated pupil, haloes, and nausea, and is an emergency that anticholinergic and sympathomimetic drugs can precipitate.

Prostaglandin analogues are first-line for open-angle glaucoma; counsel on iris and periocular pigmentation and eyelash growth.

Sore throat with a Centor or McIsaac score of 0 or 1 does not warrant antibiotics, and most acute otitis media in a well child over two years can be managed with watchful waiting.

Last updated: August 2026

6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy

Exam Focus: These systems supply many of the minor-ailment and nonprescription items on the Evaluating Examination. The recurring test is whether you can separate the condition that a pharmacist manages from the one that must be referred within hours.

Topical Corticosteroids: The Governing Rules

Topical corticosteroid selection is governed by potency, vehicle, site, and duration.

  • Potency group Representative agent Typical use
  • Low Hydrocortisone 0.5% to 2.5% Face, eyelids, flexures, genitals, infants
  • Moderate Betamethasone valerate 0.1%, triamcinolone 0.1% Trunk and limbs, moderate eczema
  • High Betamethasone dipropionate 0.05% Thick plaques, palms and soles
  • Very high Clobetasol propionate 0.05% Short courses on resistant plaques; never on the face

Vehicle matters as much as potency: ointments are the most occlusive and potent for dry, lichenified skin; creams suit weeping or intertriginous areas; lotions, foams, and solutions suit hair-bearing skin.

Quantify the dose with the fingertip unit — the amount squeezed from a 5 mm nozzle over the distal phalanx, roughly 0.5 g, which covers an area equal to two adult palms. Adverse effects of prolonged use are skin atrophy, striae, telangiectasia, hypopigmentation, perioral dermatitis, and, over large surface areas, hypothalamic-pituitary-adrenal axis suppression.

Atopic Dermatitis, Psoriasis, and Acne

Atopic dermatitis management is built on emollients applied liberally and frequently, corticosteroid for flares, and trigger avoidance. Steroid-sparing options for the face and flexures include topical calcineurin inhibitors (tacrolimus, pimecrolimus) and crisaborole. Moderate to severe disease is escalated to dupilumab or a Janus kinase inhibitor. Sedating antihistamines help sleep but do not treat the itch of eczema, which is not histamine-driven.

Psoriasis is an immune-mediated hyperproliferative disorder producing well-demarcated plaques with silvery scale. Topical therapy combines a corticosteroid with a vitamin D analogue such as calcipotriol; coal tar and salicylic acid remain useful adjuncts. Moderate to severe or joint-involving disease moves to phototherapy, methotrexate, acitretin (teratogenic, with alcohol avoidance because it converts to long-lived etretinate), apremilast, or biologics targeting tumour necrosis factor, interleukin-17, or interleukin-23. Lithium, beta-blockers, antimalarials, and abrupt systemic corticosteroid withdrawal can precipitate flares.

Acne vulgaris therapy is matched to lesion type:

Comedonal: topical retinoid (adapalene, tretinoin). Apply at night to dry skin; expect an initial purge and photosensitivity.

Inflammatory: add benzoyl peroxide, which also prevents antibiotic resistance, or a topical antibiotic in combination — never a topical antibiotic alone.

Moderate to severe: oral tetracyclines (doxycycline, minocycline) for a limited course, or combined oral contraceptives and spironolactone in appropriate patients.

Severe nodulocystic or scarring: isotretinoin . It is highly teratogenic; in Canada it is dispensed under a pregnancy prevention programme requiring negative pregnancy testing before starting and monthly thereafter, two reliable contraceptive methods, and no blood donation during therapy and for one month afterwards. Monitor lipids and liver enzymes, and counsel on dryness, photosensitivity, and mood change.

  • Ophthalmic Disorders
  • Glaucoma

Open-angle glaucoma is a chronic, painless optic neuropathy. First-line therapy is a prostaglandin analogue (latanoprost, bimatoprost) given once nightly; counsel on conjunctival hyperemia, permanent iris darkening, periocular pigmentation, and eyelash lengthening. Alternatives are topical beta-blockers (avoid in asthma, COPD, and bradyarrhythmia because of systemic absorption), alpha-2 agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors.

Teach punctal occlusion : after instilling a drop, close the eye and press the inner canthus for one to two minutes. This reduces systemic absorption, which matters most for timolol. Separate different drops by at least five minutes and instil suspensions last.

Acute angle-closure glaucoma is an emergency: severe eye pain, a red eye, blurred vision with haloes around lights, a fixed mid-dilated pupil, headache, and vomiting. Anticholinergics, sympathomimetic decongestants, and topiramate can precipitate it in anatomically predisposed eyes. Refer immediately.

Red eye triage

Presentation Likely cause Action

Bilateral itch, stringy discharge, seasonal Allergic conjunctivitis Ocular antihistamine or mast cell stabiliser

Watery discharge, recent upper respiratory infection, one eye then the other Viral conjunctivitis Supportive care, strict hygiene

Purulent discharge, lids stuck on waking Bacterial conjunctivitis Often self-limiting; topical antibiotic where indicated

Pain, photophobia, reduced vision, contact lens wear, or trauma Keratitis, uveitis, angle closure Urgent referral

Never recommend an ocular corticosteroid without a diagnosis; used in herpes simplex keratitis it can lead to corneal perforation.

Dry eye and macular degeneration

Dry eye is managed with preservative-free artificial tears for frequent dosing, lid hygiene, and review of contributing anticholinergic drugs. In intermediate age-related macular degeneration, an antioxidant and zinc supplement of the AREDS2 formulation slows progression; the beta-carotene of the original formulation was removed because it increased lung cancer risk in smokers.

Ear, Nose, and Throat

Allergic rhinitis responds best to an intranasal corticosteroid , which outperforms oral antihistamines for congestion. Counsel on the technique that prevents epistaxis: aim the spray away from the septum, toward the outer wall of the nostril, and do not sniff hard. Second-generation oral antihistamines are useful for sneeze and itch. Topical decongestants must be limited to three consecutive days to avoid rhinitis medicamentosa.

Sore throat is triaged with the Centor criteria as modified by McIsaac: fever above 38 degrees Celsius, absence of cough, tender anterior cervical lymphadenopathy, tonsillar exudate, and age (3 to 14 adds a point, 45 or older subtracts one). A score of 0 or 1 needs no antibiotic or testing. Higher scores prompt testing, with penicillin or amoxicillin first-line and a macrolide reserved for true penicillin allergy.

Acute otitis media in a well child older than two years with mild symptoms can be managed with analgesia and watchful waiting for 48 hours. Amoxicillin at high dose is first-line when antibiotics are indicated. Otitis externa ("swimmer's ear") is treated with topical drops; an intact tympanic membrane must be confirmed before using aminoglycoside-containing drops because of ototoxicity risk.

Cerumen impaction is treated with a softening agent such as mineral oil or carbamide peroxide; irrigation is contraindicated with perforation, tubes, or recent ear surgery. Ménière disease combines episodic vertigo, fluctuating hearing loss, tinnitus, and aural fullness, and is managed with sodium restriction, diuretics, and vestibular suppressants for acute attacks.